News

Invented by Zealand and licensed to Helsinn, elsiglutide is a potent and selective glucagon-like-peptide-2 (GLP-2) receptor agonist and is developed for use in cancer supportive care. Helsinn evaluated

The fourth generation macrolide antibiotic is currently in Phase 3 development for community-acquired bacterial pneumonia (CABP) in adults. Cempra chief executive officer Prabhavathi Fernandes said BARDA has recognized

The Series A financing will be used to develop PH46A, as a potential first-in-class oral small molecule drug for the treatment of inflammatory bowel disease (IBD), as well

Expected to be issued in the next few months, the fifth US patent will provide additional protection to Zecuity, the sumatriptan iontophoretic transdermal system. Other US patents covering

Designed to provide sensitive and healthy methods for capturing and purification of DNA sample libraries, SeqCap EZ Pure Capture Bead Kit enables high-quality targeted sequencing results. Roche sequencing

The distribution deal follows the Mexican regulatory approval for Sucanon that contains natural ingredients as an OTC treatment for Type-II diabetes. With a possibility to continue further, the

The intellectual property rights will be leveraged in the development of an abuse-deterrent formulation technology for extended-release morphine sulfate. Grunenthal CEO Harald Stock said, "This is certainly another

Capabilities of both the companies will be leveraged through a new business model in the alliance that involves two elements. The first element of the alliance includes a

Vault PromoMats function accelerates approval, disbursal, and retrieval of marketing materials and allows companies to capitalize based on the integration with Veeva CRM. The combination of Vault PromoMats